Entera Bio Accelerates Its Hypoparathyroidism Program as a Catalyst-Heavy Year Takes Shape

Newly announced expanded OPKO partnership set to advance oral hypoparathyroidism treatment candidate toward the clinic, adding momentum to a pipeline already approaching Phase 3 in osteoporosis

Entera Bio’s latest announcement builds naturally on a trajectory that has been forming over the past year. By expanding its collaboration with OPKO Health to accelerate development of an oral long-acting PTH tablet for hypoparathyroidism, the company adds a second meaningful value driver to a pipeline that already includes a Phase 3–approaching osteoporosis program – and does so in a way that sharpens timelines rather than distracting from them.

The result is a company entering 2026 with multiple programs advancing in parallel and a string of milestones ahead – particularly notable for a company recently trading at a market capitalization of just ~$54 million. For context, at the start of November – prior to the company outlining several of its upcoming milestones – the stock was trading above $3, nearly three times its recent ~$1.20 level. Since then, valuation has compressed despite the pipeline moving meaningfully forward.

Hypoparathyroidism Is Now a Commercially Validated Market

Hypoparathyroidism has quietly shifted from an under-served endocrine condition to a fully validated commercial category. Ascendis Pharma’s Yorvipath accelerated adoption of PTH replacement therapy and demonstrated payer willingness to reimburse for long-term therapy. The commercial numbers help explain why this market is now taken seriously: Yorvipath generated over €100 million in revenue in Q2 2025, supported by continued U.S. uptake with approximately 3,100 unique patient enrollments as of June 30, 2025.

Those data points matter because they validate not just the biology, but the economics – and they reinforce the underlying logic that has driven continued innovation in the space: hypoparathyroidism is lifelong, and therapy needs to work for decades, not quarters.

What remains open is not whether PTH replacement works, but whether it can be delivered in a form that aligns with decades of real-world use.

A Program Years in the Making, Now Moving Faster

Entera’s hypoparathyroidism program did not emerge in response to recent commercial successes elsewhere; it has been under development for several years. In 2021, the company published Phase 2 clinical data demonstrating clinically meaningful biochemical effects with an oral PTH(1–34) tablet in hypoparathyroidism patients – supporting the feasibility of oral hormone replacement in humans, while also surfacing a central challenge: dosing practicality.

Entera’s more recent work has been aimed squarely at that constraint. In December 2025, the company reported new preclinical data supporting further development of a proprietary long-acting oral PTH program, including sustained calcium elevation for more than three days from a single oral tablet in animal models – supporting a path toward once-daily dosing. Entera also noted that the program already holds orphan drug designation in both the U.S. and EU.

Today’s announcement connects that December inflection point to a concrete development plan.

What the OPKO Expansion Actually Changes

OPKO and Entera have been partners since late 2023, working together on oral peptide programs including oxyntomodulin and GLP-2. The current announcement expands that collaboration to include a long-acting PTH analog program designed for hypoparathyroidism and explicitly targets the practical endgame: a once-daily oral tablet regimen.

Following favorable PK/PD data reported in late 2025, the companies elected to accelerate development and now expect to file an IND application in late 2026. Under the expanded agreement, OPKO and Entera will share ownership and development costs equally for this long-acting PTH hypoparathyroidism program.

The key takeaway isn’t deal mechanics – it’s acceleration. This is not a new partnership announcement; it’s an existing collaboration extending into a second major endocrine franchise, with a defined next regulatory step.

EB613: A Larger Market, Nearer-Term Decisions

While hypoparathyroidism is increasingly in focus due to commercial validation, Entera’s most advanced program remains EB613, its oral anabolic PTH therapy for osteoporosis.

Osteoporosis is a vastly larger market and remains significantly undertreated, despite the availability of effective injectable therapies. Injection burden continues to limit adoption, even among high-risk patients – making convenience and adherence less a marketing advantage than a core driver of real-world impact.

Entera has already completed a placebo-controlled Phase 2 study of EB613 demonstrating favorable pharmacodynamic effects and improvements in bone mineral density. More recently, the regulatory environment shifted in a way that directly de-risks Entera’s path forward: on December 19, 2025, the FDA qualified total hip bone mineral density as a validated surrogate endpoint to support clinical trials in postmenopausal women with osteoporosis at risk for fracture.

Against that backdrop, Entera has communicated plans to submit its final Phase 3 protocol in Q1 2026 and expects readouts from a next-generation EB613 Phase 1 bridging study within the same quarter, per its January 2026 corporate priorities update.

Strategic optionality is also increasingly explicit. As Entera stated recently, “Entera continues to engage in strategic partnership discussions across its pipeline to optimize the development and commercialization pathway for its first-in-class oral peptide programs.”

One additional data point reinforcing internal alignment: in late December 2025, Entera’s CEO, Miranda Toledano, disclosed an open-market purchase of 11,000 shares at an average price of approximately $1.81 per share.

Two Programs, One Underlying Capability

Taken together, EB613 and the accelerated hypoparathyroidism program illustrate something important – without requiring Entera to lead with a “platform company” label.

Both programs rely on the same core capability: delivering peptide hormones orally in a way that preserves pharmacological effect. That capability now supports a late-stage osteoporosis program and a hypoparathyroidism candidate moving back toward the clinic, while also underpinning earlier partnered programs with OPKO.

At a time when the pharmaceutical industry is increasingly focused on reducing injection burden across chronic diseases, this underlying capability is becoming more strategically relevant – not as a story in itself, but as the engine behind multiple parallel development paths.

Looking Ahead

Entera enters 2026 with a combination that is unusual for a company of its size: a Phase 3–ready osteoporosis asset, an accelerated hypoparathyroidism program with a defined path toward an IND filing, and multiple near-term catalysts across both.

The expanded OPKO partnership expansion reinforces the direction Entera has already been moving in while accelerating it – advancing practical, oral alternatives in hormone markets that have proven both clinically and commercially meaningful.